The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus
Open accessAbstract
Background & Aims Limited evidence suggests that proton pump inhibitors (PPI), non-steroidal anti inflammatory drugs (NSAID)/aspirin and statins may be associated with low risk of esophageal neoplasia. However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (EAC) in patients with existing Barrett’s esophagus (BE) is unclear. Methods We conducted a nested case-control study in a cohort of patients with BE identified in the national Department of Veterans Affairs (VA) computerized databases. Cases with incident EAC were matched by incidence density sampling to controls with BE who remained without EAC at the date of the EAC diagnosis for the corresponding case. We identified prescriptions for PPI, NSAID/aspirin, and statins that were filled between BE diagnosis and EAC diagnosis. Incidence density ratios were calculated using conditional logistic regression models that adjusted for race, outpatient encounters, a disease comorbidity index, and socio-economic status. Results In a cohort of 11,823 patients with first time BE diagnosis, we examined 116 EAC cases and 696 matched controls. Most cases and controls had at least one filled PPI prescription (95% vs. 94%, p=0.5). In this setting of almost universal PPI use, filled NSAID/aspirin prescriptions were associated with a reduced risk of EAC (adjusted incidence density ratio: 0.64; 95% CI, 0.42–0.97). Filled statin prescriptions were also associated with a reduction in EAC risk (0.55; 95% CI, 0.36–0.86), with a significant trend toward greater risk reduction with longer duration of statin use. However, the strong inverse associations with even short periods of use raise concerns of uncontrolled confounding. Conclusion This observational study indicates that in patients with Barrett’s esophagus using PPI, NSAID/aspirin or statin therapy might reduce the risk of developing esophageal adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
Nguyen, D. M., El-Serag, H. B., Henderson, L., Stein, D., Bhattacharyya, A., & Sampliner, R. E. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.001 · Cited by 159
Self-citation
Cited by
Epidemiology of esophageal cancer: update in global trends, etiology and risk factors
Uhlenhopp, D. J., Then, E. O., Sunkara, T., & Gaduputi, V. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01237-x · Cited by 766
The Epidemiology of Esophageal Adenocarcinoma
Coleman, H. G., Xie, S.-H., & Lagergren, J. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.07.046 · Cited by 549
Recent developments in esophageal adenocarcinoma
Lagergren, J., & Lagergren, P. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21185 · Cited by 309
Singh, S., Garg, S. K., Singh, P. P., Iyer, P. G., & El-Serag, H. B. (2014) · Gut · doi:10.1136/gutjnl-2013-305997 · Cited by 298
Self-citationEpidemiology of Esophageal Cancer
Wheeler, J. B., & Reed, C. E. (2012) · Surgical Clinics of North America · doi:10.1016/j.suc.2012.07.008 · Cited by 255
Metadata
- Authors
- Nguyen, D. M., Richardson, P., & El–Serag, H. B.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 138
- Issue
- 7
- Pages
- 2260-2266
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2018202257
- Cited by
- 186
- References
- 1
- FWCI
- 22.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus. https://app.cochat.ai/papers/10.1053/j.gastro.2010.02.045
- The paper
- Nguyen, D. M., Richardson, P., & El–Serag, H. B. (2010). Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus. Gastroenterology. https://doi.org/10.1053/j.gastro.2010.02.045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.